On the first day of the 52nd Annual Meeting of Japan Society of Clinical Oncology which is being held on August 28 – 30 in Yokohama City, Japan, Shinichi, Suzuki, a thyroid surgeon from Fukushima University in charge of the Fukushima thyroid ultrasound examination, presented some details of the surgical cases in a presentation titled “Treatment of childhood thyroid cancer in Fukushima” during the Organ Specific Symposium 03: Up-to-Date Thyroid Cancer Treatment – Thyroid Cancer in Children and Adolescents. Suzuki has consistently declined to reveal these details during sessions of the Prefectural Oversight Committee Meeting for Fukushima Health (Management) Survey as well as the Fukushima Thyroid Examination Expert Subcommittee meetings.
From the news report, which is the only material available online containing information revealed by Suzuki, Fukushima Medical University operated on 54 of the 57 surgical cases, with 45 meeting the criteria for absolute surgical indications described at the August 24 Oversight Committee Meeting for Fukushima Health Survey, excerpted below:
(2) Regarding indications for surgery
In Japan, when thyroid cancer is suspected, absolute indications for surgery include pre-surgical tumor with a diameter equal to or greater than 10 mm, lymph node metastases, extrathyroidal extension, and distant metastases. Furthermore, tumors with a diameter of 10 mm or smaller, so-called microcarcinomas, might be followed with observation in adults. However, surgery might be indicated for microcarcinomas if they are accompanied by lymph node metastasis, distant metastasis or extrathyroidal spread, or in close proximity to the recurrent laryngeal nerve or the trachea.
In regards to the timing and place of Suzuki’s report, although it would seem more appropriate for him to present the details at the Prefectural Oversight Committee Meeting for Fukushima Health Survey, the following fact must be addressed: The cases which advance beyond a certain point of the secondary examination, such as biopsy, are no longer part of the Fukushima thyroid ultrasound examination as screening but rather go under regular medical care. Therefore it appears legitimate that Suzuki presented them at an academic conference first.
However, it’s a different matter whether this was a moral act. Suzuki has been repeatedly asked by committee members and journalists to disclose more details about the surgical cases. There have been many speculations about whether there have been overdiagnosis and overtreatment, creating a lot of arguments and confusion. Suzuki maintained Fukushima Medical University was following the diagnostic criteria, yet he would not reveal details. He said at one of the committee meetings that Fukushima Medical University would be fulfilling its social responsibility towards Fukushima residents by submitting academic papers to inform the world of what is happening. Although the Fukushima Health Survey is intended to watch over the health of residents and stand by them, many Fukushima residents distrust Fukushima Medical University enough to refuse participation. Fukushima Medical University’s social responsibility should be, first and foremost, to maintain an honest and transparent relationship with residents. In that sense, Suzuki has effectively failed them.
By the way, those over age 18 no longer qualify for free medical care for Fukushima children. As 57 of the 104 confirmed or suspected of cancer were over age 18, more than half of them are facing a financial burden (Japan’s National Health Insurance requires 30% copay) in addition to a physical and psychological burden of having cancer, as the treatments and follow-ups are conducted as part of regular medical care.
Incidentally, President of the 52nd Annual Meeting of Japan Society of Clinical Oncology, Seiichi Takenoshita, is Professor and Chairman of the Department of Organ Regulatory Surgery, Fukushima Medical University. In other words, he is Suzuki’s boss.
Suzuki is scheduled to speak again during the August 30 Fukushima Session called “Message from Fukushima,” featuring Shunichi Yamashita as a keynote speaker. Yamashita will speak on “Scope for the future of Fukushima; resilience creation after the nuclear accident.” Suzuki’s presentation is called “Radiation exposure and thyroid ultrasound examination from the data of the Fukushima Health Management Survey.”